Novogen Limited (NASDAQ:NVGN) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday, August 1st.
Separately, Zacks Investment Research downgraded Novogen Limited from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd.
Shares of Novogen Limited (NASDAQ NVGN) remained flat at $3.28 during mid-day trading on Tuesday. The stock had a trading volume of 27 shares. The stock’s 50 day moving average price is $2.59 and its 200-day moving average price is $1.55. Novogen Limited has a 52-week low of $0.70 and a 52-week high of $3.82. The stock’s market cap is $15.85 million.
WARNING: “Novogen Limited (NVGN) Downgraded by ValuEngine” was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/19/novogen-limited-nvgn-lowered-to-sell-at-valuengine-updated-updated.html.
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Novogen Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novogen Limited and related companies.